[2] REVIEWS, EDITORIALS AND BOOK CHAPTERS
1. Mikhailidis DP, Jeremy JY, Dandona P. Urinary bladder prostanoids: their synthesis, function and possible role in the pathogenesis and treatment of disease. J Urol 1987; 59: 40 - 44.
2. Mikhailidis DP, Jeremy JY, Dandona P. Editorial: Why a review journal? Prostagl Leukotr Essntl Fatty Acids - Revs 1988; 32: 155 - 156.
3. Mikhailidis DP, Jeremy JY, Dandona P. Editorial: Therapeutic applications of prostanoids and essential fatty acids. Prostagl Leukotr Essntl Fatty Acids - Revs 1988; 33: 205 - 206.
4. Mikhailidis DP, Jeremy JY, Dandona P. The role of prostaglandins, leukotrienes and essential fatty acids in the pathogenesis of the complications associated with diabetes mellitus. Prostagl Leukotr Essntl Fatty Acids - Revs 1988; 34: 193 - 195.
5. Jeremy JY, Mikhailidis DP, Dandona P. Role of eicosanoids in obstetrics, gynae-cology and fertility. Prostagl Leukotr Essntl Fatty Acids - Revs 1988; 34: 193 - 195.
6. Jeremy JY, Mikhailidis DP, Dandona P. Excitatory receptor-prostanoid synthesis coupling in smooth muscle: mediation by calcium, protein kinase C and G proteins. Prostagl Leukotr Essntl Fatty Acids - Revs 1988; 34: 215 - 227.
7. Mikhailidis DP, Jeremy JY. Platelet function - the role of essential fatty acids and eicosanoids. Prostagl Leukotr Essntl Fatty Acids - Revs 1989; 35: 187 - 188.
8. Mikhailidis DP, Barradas MA. Low molecular weight heparin(oid)s: are they the answer to heparin-associated thrombocytopenia (and thrombosis)? J Drug Develop 1989; 1: 265 - 273.
9. Mikhailidis DP, Barradas MA. Guest Editorial: Haemostatic effects of lipid lowering drugs. J Drug Develop 1989; 2: 69 - 71.
10. Jeremy JY, Mikhailidis DP. Non-steroidal anti-inflammatory drug-induced gastropathy: are non-acidic pro-drugs the answer? Prostagl Leukotr Essntl Fatty Acids - Revs 1989; 37: 215 - 218.
11. Mikhailidis DP, Jeremy JY. The effects of various nutrients on eicosanoid synthesis. Prostagl Leukotr Essntl Fatty Acids - Revs 1989; 37: 213 - 214.
12. Jeremy JY, Mikhailidis DP. Prostanoids and impotence. Br J Sex Med 1989; 16: 411 - 413.
13. Mikhailidis DP, Jeremy JY, Dandona P. A review journal two years on. Prostagl Leukotr Essntl Fatty Acids - Revs 1989; 38: 213.
14. de Almeida PJ, Pires JGP, Marquezini AJ, Barradas MA, Mikhailidis DP. Platelets, vessels and coagulation: basic mechanisms and drug actions. J Drug Develop 1990; 2: 227 - 240.
15. Mikhailidis DP, Barradas MA, Jeremy JY. The effect of ethanol on platelet function and vascular prostanoids. Alcohol 1990; 7: 171 - 180.
16. Jeremy JY, Mikhailidis DP. Prostaglandins and the penis: possible role in the pathogenesis and treatment of impotence. Sexual Marital Ther 1990; 5; 155 - 165.
17. Mikhailidis DP, Jeremy JY, Shoukry K, Virag R. Eicosanoids, impotence and pharmacologically induced erection. Prostagl Leukotr Essntl Fatty Acids 1990; 40: 239 - 242.
18. Peplow PV, Mikhailidis DP. Platelet-activating factor (PAF) and its relation to prostaglandins, leukotrienes and other aspects of arachidonate metabolism. Prostagl Leukotr Essntl Fatty Acids 1990; 41: 71 - 82.
19. Mikhailidis DP, Jeremy JY, Goto Y, Diana J, Caldwell ADS. Why a journal of smoking-related disorders? J Smoking-Related Disorders 1990; 1: 1.
20. Jeremy JY, Mikhailidis DP. Smoking and vascular prostanoids: relevance to the pathogenesis of atheroma and thrombosis. J Smoking-Related Disorders 1990; 1: 59 -69.
21. Jeremy JY, Mikhailidis DP. Guest Editorial: NSAID efficacy and side-effects: are they wholly prostaglandin-mediated? J Drug Develop 1990; 3: 3 - 4.
22. Mikhailidis DP, Barradas MA, Jeremy JY. Platelet hyper-reactivity: a predictor of cardiac events and death from myocardial infarction. Platelets 1990; 1: 217 - 218.
23. Jeremy JY, Mikhailidis DP. Vascular and platelet eicosanoids, smoking and atherosclerosis. Adv Exper Med Biol 1990; 273: 135 - 146.
24. Mikhailidis DP, Jeremy JY. Migraine and smoking: is there an association? J Smoking-Related Disorders 1991; 2: 85 - 86.
25. Jeremy JY, Mikhailidis DP. Anti-oestrogenic effects of cigarette smoking in women: pathological implications. J Smoking-Related Disorders 1991; 2: 203 - 208.
26. Caldwell ADS, Mikhailidis DP, Jeremy JY. Aspects of smoking cessation. J Smoking-Related Disorders 1992; 3: 1 - 2.
27. Mikhailidis DP. Weight gain and smoking cessation - is there a solution? J Drug Develop 1992; 5: 3 - 4.
28. Mikhailidis DP. Smoking and the young. J Smoking-Related Disorders 1992; 3: 195 - 196.
29. Colvin BT, Mikhailidis DP. Current topics in thrombosis. J R Soc Med 1993; 86: 55 - 56 (meeting report).
30. Barradas MA, Mikhailidis DP. Serotonin, histamine and platelets in vascular disease with special reference to peripheral vascular disease. Brazilian J Med Biol Res 1992; 25: 1063 - 1076.
31. Jeremy JY, Gill JK, Mikhailidis DP. Assessment of calcium dynamics in platelets. Equine Vet J 1993; 25: 6 - 7.
32. Barradas MA, Mikhailidis DP. The use of platelets as models for neurons: possible applications to the investigation of eating disorders. Biomed Pharmacother 1993; 47: 11 - 18.
33. Breimer LH, Mikhailidis DP. An MD for Europe? Br J Hosp Med 1993; 49: 459 -460.
34. Jeremy JY, Mikhailidis DP. Eicosanoids and drug action. J Drug Develop 1993; 6: 1 - 3.
35. Mikhailidis DP, Jeremy JY. Il ruolo delle prostaglandine nell'erezione e nell'impotenza. In: A. Ledda Ed. Andrologia Vascolare. Torino Edizioni Minerva Medica 1993.
36. Thompson CS, Mikhailidis DP. Clinical biochemistry in experimental diabetes mellitus. In: AK Sharma Ed. Diabetes mellitus and its complications: an update. MacMillan 1993; p. 206 - 214.
37. Mikhailidis DP, Barradas MA, Jeremy JY. Platelet and vascular dysfunction in diabetes mellitus. In: AK Sharma Ed. Diabetes mellitus and its complications: an update. MacMillan 1993; p. 454 - 460.
38. Mikhailidis DP, Jeremy JY. Smoking and erectile impotence. Int Angiol 1993; 12: 297 - 298.
39. Bakker WW, Poelstra K, Barradas MA, Mikhailidis DP. Platelets and ectonucleo-tidases. Platelets 1994; 5: 121 - 129.
40. Jeremy JY, Nystrom ML, Mikhailidis DP. Eicosanoids and septicaemia. Prostagl Leukotr Essntl Fatty Acids 1994; 50: 287 - 297.
41. Jeremy JY, Stansby G, Mikhailidis DP, Hamilton G. NSAIDs: possible use in the prevention of restenosis. J Drug Develop 1994; 6: 91 - 92.
42. Mikhailidis DP, Jeremy JY. Meetings report: Drugs and smoking cessation - an update from the international congress on smoking cessation. J Drug Develop 1994; 6: 205 - 206.
43. Mikhailidis DP, Jeremy JY, Dickerson JWT. Smoking and Health - a new series for the Journal of the Royal Society of Health. J R Soc Health 1994; 114: 197.
44. Mikhailidis DP, Winder AF. A place for fibrinogen-lowering drugs in cardio-vascular disease? J Drug Develop 1995; 7: 3 - 5.
45. Jeremy JY, Mikhailidis DP, Pittilo RM. Cigarette smoking and cardiovascular disease. J R Soc Health 1995; 115: 289 - 295.
46. Mikhailidis DP, Winder AF, Jeremy JY, Pittilo RM. Endothelial injury in vascular disease. J R Soc Med 1996; 89: 175P- 176P (meeting report).
47. Nair DR, Mikhailidis DP, Winder AF. Ischaemic heart disease among asian immigrants in UK. ODA News Rev 1996; 6: 17 - 19.
48. Mikhailidis DP, Spyropoulos KA. The effect of tamoxifen on lipid and haemostatic predictors of ischaemic heart disease. J Drug Develop 1996; 8: 19 - 24.
49. Mikhailidis DP, Ganotakis ES. Plasma albumin and platelet function: relevance to atherogenesis and thrombosis. Platelets 1996; 7: 125 - 137.
50. Ganotakis ES, Mikhailidis DP. Cardiovascular risk factor management - new drugs will provide a bright future! J Drug Develop 1996; 8: 57 - 60.
51. Ganotakis ES, Mikhailidis DP. Bezafibrate: treating hyperlipidaemias as well as other cardiovascular risk factors. Today's Therap Trends 1996; 13: 231 - 249.
52. Breimer LH, Mikhailidis DP. Coagulation and fibrinolytic factors as predictors of cardiovascular disease. Risk 1996; 4: 10 - 13.
53. Thompson CS, Mikhailidis DP. Streptozotocin-induced ketoacidosis and non-ketonuric diabetes in the rat: useful models for drug action. J Pharm Med 1996; 6: 57 - 85.
54. Panayi G, Mikhailidis DP. Why a Hellenic Medical Journal? Hellenic Med J 1997; 1 (1): III.
55. Panayi G, Mikhailidis DP. The Hellenic Medical Journal: where are we now? Hellenic Med J 1997; 1 (2): III.
56. Mikhailidis DP, Spyropoulos KA, Winder AF. Fibrinogen as a predictor of ischaemic heart disease. Hellenic Med J 1997; 1 (2): 79 - 81.
57. Mikhailidis DP, Ganotakis ES. Leading Article: Risk factors for restenosis following angioplasty or bypass. Interventional Cardiol Monitor 1997; 4: 2 - 7.
58. Breimer LH, Ganotakis ES, Mikhailidis DP. Fibrinogen as a cardiovascular risk factor. Rev Port Cardiol 1997; 16: 245 - 50.
59. Mikhailidis DP, Ganotakis ES,JagroopIA.Pathophysiology ofheparin-induced thrombocytopenia (HIT). Platelets 1997; 8: 66 - 68.
60. Amiral J, Baglin TP, Magnani HN,Mikhailidis DP. Heparin-induced thrombocytopenia: an underdiagnosed syndrome? Consensus overview. Platelets 1997; 8: 82.
61. Jeremy JY, Mikhailidis DP. Prostaglandins and the aetiology and treatment of erectile dysfunction. In: Ledda A (Ed.) Vascular Andrology. Erectile dysfunction, priapism and varicocele. Berlin. Springer-Verlag 1996; 19 - 27.
62. Papadakis JA, Mikhailidis DP, Winder AF. Lipids and stroke: neglect of a useful preventive measure? Cardiovasc Res 1998; 40: 265 - 271.
63. Mikhailidis DP, Papadakis JA, Ganotakis ES. Smoking, diabetes and hyperlipidaemia. J R Soc Health 1998; 118: 91 - 93.
64. Jeremy JY, Mikhailidis DP. Cigarette smoking and erectile dysfunction. J R Soc Health 1998; 118: 151 - 155.
65. Papadakis JA, Mikhailidis DP. Alcohol and vascular disease: an overview of the literature. Vasc Disease 1998; 1: 34 - 43.
66. Pasini E, Mori L, Coates R, Mikhailidis DP, Leone A. Endothelial dysfunction and ischaemic heart disease: effects of smoking. Hellenic Med J 1998; 2: 15 - 19.
67. Lewis B, Mikhailidis DP, Editorial Consultants. Ciprofibrate in primary care. London, Current Medical Literature 1998; 1 - 22.
68. Balas P, Toutouzas P, Sgouropoulos P, Mikhailidis DP. Atherothrombotic disease and platelets. Hellenic Med J 1998; 2: 73- 76.
69. Papadakis JA, Mikhailidis DP, Winder AF. Effect of tamoxifen on serum triglyceride levels. Hellenic Med J 1998; 2: 51 - 54.
70. Mikhailidis DP, JagroopIA. Is clopidogrel markedly superior to aspirin in patients with peripheral vascular disease? Platelets 1998; 9: 273 - 278.
71. Mikhailidis DP, Ganotakis ES,Papadakis JA, Jeremy JY. Smoking and urological disease. J R Soc Health 1998; 118: 218 - 220.
72. Khan MA, Thompson CS, Mumtaz FH, Jeremy JY, Morgan RJ, Mikhailidis DP. Role of prostaglandins in the urinary bladder: an update. Prostagl Leukotr Essntl Fatty Acids 1998; 59: 415 - 422.
73. Khan MA, Thompson CS, Sullivan ME, Dashwood MR, Jeremy JY, Morgan RJ, Mikhailidis DP. Endothelin and erectile dysfunction: a target for pharmacological intervention? Exp Opin Invest Drugs 1998; 7: 1759 - 1767.
74. Khan MA, Thompson CS, Mumtaz FH, Morgan RJ, Mikhailidis DP. Pathogenesis of benign prostatic hyperplasia (BPH): An update for urological surgeons. Surgical Chronicles 1998; 1; 40 - 44.
75. Mumtaz FH, Khan MA, Sullivan ME, Thompson CS, Mikhailidis DP, Morgan RJ, Dashwood MR. Potential role of endothelin and nitric oxide in the physiology and patho-physiology of the lower urinary tract. Endothelium 1999; 7: 1 - 9.
76. Hartwright D, Baghai M, Lagattolla NRF, Mikhailidis DP. Medical therapy in peripheral arterial disease. Vasc Disease 1999; 2: 2 - 10.
77. Milionis HJ, Mikhailidis DP, Winder AF. Platelets and lipoprotein (a): a brief review of their role in the pathogenesis of atherothrombosis. Platelets 1999; 10: 277 -284.
78. Khan MA, Thompson CS, Sullivan ME, Jeremy JY, Mikhailidis DP, Morgan RJ. The role of prostaglandins in the aetiology and treatment of erectile dysfunction. Prostagl Leukotr Essntl Fatty Acids 1999; 60: 169 - 174.
79. Sullivan ME, Thompson CS, Dashwood MR, Khan MA, Jeremy JY, Morgan RJ, Mikhailidis DP. Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease? Cardiovasc Res 1999; 43: 658 - 665
80. Mumtaz FH, Khan MA, Thompson CS, Morgan RJ, Mikhailidis DP. Nitric oxide and the lower urinary tract: physiological and pathological implications. Br J Urol 2000; 85: 567 - 578.
81. Milionis HJ, Elisaf MS, Mikhailidis DP. Platelets and lipid lowering interven-tions. Platelets 1999; 10: 357 - 367.
82. Milionis HJ, Winder AF, Mikhailidis DP. Lp(a) and stroke. J Clin Pathol 2000; 53: 487 - 496.
83. Jeremy JY, Angelini GD, Khan MA, Mikhailidis DP, Morgan RJ, Thompson CS, Bruckdorfer KR, Naseem KM. Platelets, oxidant stress and erectile dysfunction: a hypothesis. Cardiovasc Res 2000; 46: 50 - 54.
84. Mikhailidis DP, Milionis H. Antiplatelet agents and the prevention of stroke. In: Bastounis EA Ed. 13th Congress of the European Chapter of the International Union of Angiology. Bologna, Monduzzi Editore S.p.A. 1999; 77 - 82.
85. Milionis HJ, Elisaf MS, Mikhailidis DP. Treatment of dyslipidaemias in patients with established vascular disease: a review of the fibrates. Curr Med Res Opin 2000; 16: 21 - 32.
86. Khan MA, Thompson CS, Mumtaz FH, Mikhailidis DP, Morgan RJ. Urological aspects of female sexual dysfunction. Urol Int 2000; 65: 1 - 8.
87. Papadakis JA, Ganotakis ES, Mikhailidis DP. Beneficial effect of moderate alcohol consumption on vascular disease: myth or reality? J R Soc Health 2000; 120: 11 - 15.
88. Mikhailidis DP, WierzbickiAS. HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin. Curr Med Res Opin 2000; 16: 139 - 146.
89. Khan MA, Calvert RC, Sullivan ME, Thompson CS, Mumtaz FH, Morgan RJ, Mikhailidis DP. Normal and Pathological erectile function: the potential clinical role of endothelin-1 antagonists. Curr Drug Targets 2000; 1: 247 - 260.
90. Khan MA, Morgan RJ, Mikhailidis DP.The molecular basis of penile erection. Curr Med Res Opin 2000; 16 (Suppl. 1): s21 - s30.
91.Mikhailidis DP,Khan MA,Milionis HJ,Morgan RJ. The treatment of hypertension in patients with erectile dysfunction. Curr Med Res Opin 2000; 16 (Suppl. 1): s31 - s36.
92.Khan MA,Mikhailidis DP,Morgan RJ. Sildenafil: a urologist’s view. Curr Med Res Opin 2000; 16 (Suppl. 1): s48 - s58.
93. Belcaro G, Khan MA, Ledda A, Mikhailidis DP and the consensus participants. Consensus statement. Curr Med Res Opin 2000; 16 (Suppl. 1): s76 -s78.
94.Mikhailidis DP, WierzbickiAS. Editorial Comment: Attaining United States andEuropean Guideline LDL-C cholesterol Levels with Simvastatin in Patients with Coronary Heart Disease (the GOALLS study)Curr Med Res Opin 2000; 16: 205 - 207.
95.Sullivan ME, Mumtaz FH, Khan MA, Dashwood MR, Thompson CS, Mikhailidis DP, Morgan RJ. Endothelins in the urinary tract. Br J Urol 2000; 86: 97 -106.
96. Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001; 88: 787 - 800. This review was funded by a Br J Surg Bursary.
97. Mikhailidis DP. The Doxazosin Compendium. London, Current Medical Literature 2000; 1 - 38.
98. Khan MA, Sullivan ME, Thompson CS, Dashwood MR, Morgan RJ, Mikhailidis DP. Erectile dysfunction and cardiovascular disease. Arch Hellenic Med 1999; 16: 457- 463.
99. Nair DR, WierzbickiAS, Mikhailidis DP. Time to look beyond just lowering the serum concentration of low density lipoprotein – high density lipoprotein (HDL) levels are also important. J Roy Soc Health 2001; 121: 98 - 101.
100. Mikhailidis DP. Cardiovascular risk factors in patients with peripheral vascular disease. In: D Baker ed., Primary Care of Vascular Disease. Medical Education Network (UK) Ltd. 2000; 1 - 4.
101. Papadakis JA, Milionis HJ, Press M, Mikhailidis DP. Treating dyslipidaemia in non-insulin dependent diabetes mellitus - a special reference to statins. J Diabetes Complic 2001; 15: 211 - 226.
102. Wierzbicki AS, Mikhailidis DP, Wray R. Drug treatment of combined hyperlipidemia. Am J Cardiovasc Drugs 2001; 1: 327 - 336.
103.Milionis HJ, Rizos E, Mikhailidis DP. Smoking diminishes the beneficial effect of statins: observations from the landmark trials. Angiology 2001; 52: 575 - 587.
104.Rizos E, Mikhailidis DP. Glycated haemoglobin: a predictor of vascular risk? Intnl J Diab Metab 2001; 9: 3 - 7.
105. Rizos E, Mikhailidis DP. Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention? Cardiovasc Res 2001; 52: 199 - 207.
106. Rizos E, Mikhailidis DP. Are high-density lipoprotein and triglyceride levels important in secondary prevention – impressions from the BIP and VA-HIT trials. Intnl J Cardiol 2002; 82: 199 - 207.
107. Matsagas MI, Geroulakos G, Mikhailidis DP. The role of platelets in peripheral arterial disease: therapeutic implications. Ann Vasc Surg 2002; 16: 246 - 248.
108.Masood A Khan, Robert J Morgan, Dimitri P Mikhailidis. The choice of antihypertensive drugs in patients with erectile dysfunction. Curr Med Res Opin 2002; 18: 103 - 107.
109.Cheng KS,Mikhailidis DP, Hamilton G, Seifalian AM. A review of the carotid and femoral intima-media thickness as an indicator of the presence of peripheral vascular disease and cardiovascular risk factors. Cardiovasc Res 2002; 54: 528 - 538.
110. Sacks FM, for theExpert Group on HDL Cholesterol. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert Group Recommendations. Am J Cardiol 2002; 90: 139 - 143.
111. Wierzbicki AS, Mikhailidis DP. Dose response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. Intnl J Cardiol 2002; in press.
112. Wierzbicki AS, Mikhailidis DP. Beyond LDL-C - the importance of raising HDL-C.Curr Med Res Opin2002; 18: 36 - 44.
113.Elisaf M, Mikhailidis DP. Statins and renal function. Angiology 2002; 53; 493 - 502.
114. Jagroop IA, Mikhailidis DP. Antiplatelet drugs and the prevention of stroke. In: Carotid Angioplasty and Stenting. Amor M, Bergeron P, Mathias K, Raithel D, Eds. Turin, Minerva Medica, 2002; 135 -144.
115. Mikhailidis DP, WierzbickiAS. Editorial Comment: The GREek Atorvastatin and Coronary-Heart-disease Evaluation (GREACE) study. Curr Med Res Opin2002; 18: 215 - 219.
116. Kolovou GD, Daskalova DCh, Mikhailidis DP. Apolipoprotein E polymorphism and atherosclerosis. Angiology 2003; 54: 59 - 71.
117.Khan MA, Thompson CS, Dashwood MR, Mumtaz FH, Morgan RJ, Mikhailidis DP. Endothelin-1 and nitric oxide in the pathogenesis of urinary tract disorders secondary to bladder outlet obstruction. Curr Vasc Pharmacol 2003; 1: 27 -31.
118. Mikhailidis DP. Chapter 15: Cardiovascular risk factors and peripheral arterial disease. In: Geroulakos G, van Urk H, Hobson RW, Calligaro KD eds. VASCULAR SURGERY – cases, questions and commentaries. London, Springer 2003. 113 - 120.
119. Wierzbicki AS, Mikhailidis DP, Wray R, Schachter M, Cramb R, Simpson WG, Byrne CB. Statin-fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin2003; 19: 155 - 168.
120. Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP; GREACE Study Collaborative Group. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 2003; 19: 615 - 617.
121. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003; 19: 540 - 556.
122. Tsiara S, Elisaf M, Mikhailidis DP. Influence of smoking on predictors of vascular disease. Angiology 2003; 54: 507-530.
123. Ganotakis ES, Papadakis JA, Vrentzos GE, Mikhailidis DP. The effects of antihypertensive therapy on haemostatic parameters. Curr Pharm Design 2003; 9: 2445 - 2464.
124. Milionis HJ, Elisaf MS, Mikhailidis DP. The effects of lipid-regulating therapy on haemostatic parameters. Curr Pharm Design 2003; 9: 2425 - 2443.
125. Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP. Platelets as predictors of vascular risk: is there a practical index of platelet activity? Clin Appl Thromb Hemost 2003; 9: 177 - 190.
126. Miltiadous G, Mikhailidis DP, Elisaf M. Acid-base and electrolyte abnormalities observed in patients receiving cardiovascular drugs. J Cardiovasc Pharmacol Ther 2003; 8: 267 - 276.
127. Peripheral Arterial Diseases Antiplatelet Consensus Group. Antiplatelet therapy in peripheral arterial disease. Consensus statement. Eur J Vasc Endovasc Surg 2003; 26: 1-16.
128. Daskalopoulou SS, Mikhailidis DP. How low should we go with cholesterol lowering? Hellenic J Cardiol 2004; 45: 138 - 141.
129. Milionis HJ, Athyros VG, Elisaf M,Mikhailidis DP for the GREACE study collaborative Group. Structured care with atorvastatin in patients with type 2 diabetes mellitus and coronary heart disease. Br J Diab Vasc Dis 2004; 4: 94 - 97.
130.The UK HDL-C Consensus group. Role of fibrates in reducing coronary risk: a UK consensus. Curr Med Res Opin 2004; 20:241-247.
131. Shabbir M, Mikhailidis DM, Morgan RJ. Erectile dysfunction: an underdiagnosed condition associated with multiple riskfactors.Curr Med Res Opin 2004; 20:603- 606.
132. Barnett AH, Bradbury AW, Brittenden J, Crichton B, Donnelly R,Homer-Vanniasinkam S, Mikhailidis DP, Stansby G. The role of cilostazol in the treatment of intermittent claudication. Curr Med Res Opin 2004; 20:1661- 1670.
133. Daskalopoulou SS, Athyros VG, Elisaf M, Mikhailidis DP. Uric acid levels and vascular disease. Curr Med Res Opin 2004; 20:951- 954.
134. Daskalopoulou SS, Mikhailidis DP, Elisaf M.Prevention and treatment of the metabolic syndrome.Angiology 2004; 55:589-612.
135. Daskalopoulou SS, Stansby G, Mikhailidis DP. Clopidogrel and vascular disease prevention.Curr Med Res Opin 2004; 20:1835- 1838.
136. Milionis HJ, Daskalopoulou SS, Elisaf M, Mikhailidis DP. The predictive value of lipid markers in vascular disease. Curr Pharm Des 2005;11:2209- 2224.
137. Tsimihodimos V, Miltiadous G, Daskalopoulou SS, Mikhailidis DP, Elisaf MS. Fenofibrate: metabolic and pleiotropic effects. Curr Vasc Pharmacol 2005;3:87-98.
138. Daskalopoulou SS, Mikhailidis DP. Medical management of risk factors for vascular disease. Surgery 2004; 22: 265 - 267. This text is on the Surgeons in Training Education Programme (STEP) reading list,RoyalCollege of Surgeons.
139. Kolovou GD, Mikhailidis DP, Anagnostopoulou KK, Daskalopoulou SS, Cokkinos DV. Tangier disease four decades of research: a reflection of the importance of HDL. Curr Med Chem 2006; 13:771- 782.
140. Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 2005; 11:4161- 4175.
141. Daskalopoulou SS, Daskalopoulos ME, Liapis CD, Mikhailidis DP. Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality. Curr Med Chem 2005;12:443- 452.
142. Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP, WierzbickiAS, Elisaf MS. A review of the lipid-related effects of fluvastatin. Curr Med Res Opin 2005;21:231- 244.
143. Kolovou GD, Anagnostopoulou KK, Daskalopoulou SS, Mikhailidis DP, Cokkinos DV. Clinical relevance of postprandial lipaemia. Curr Med Chem 2005;12:1931- 1945.
144. Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, Al-Saady N, Griffiths H, Hamilton G, Monkman D, Patel V, Pittard J, Schachter M. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005;21:959-969.
145. Daskalopoulou SS, Athyros VG, Hamilton G, Mikhailidis DP. Lipid-lowering therapy in patients with peripheral arterial disease. J Cardiovasc Pharmacol Ther 2005;10:145- 147.
146. Tsouli SG, Kiortsis DN, Argyropoulou MI, Mikhailidis DP, Elisaf MS. Pathogenesis, detection and treatment of Achilles tendon xanthomas.Eur J Clin Invest 2005;35:236- 244.
147. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine.Curr Med Res Opin 2005;21:457- 468.
148. Lee JD, Morrissey JR, Mikhailidis DP, Patel V. CARDS on the table: should everybody with type 2 diabetes take a statin? Curr Med Res Opin 2005;21:357- 362.
149. Daskalopoulou SS, Mikhailidis DP. The involvement of professional medical writers in medical publications.Curr Med Res Opin 2005;21:307- 310.
150. Jagroop IA, Daskalopoulou SS, Mikhailidis DP. Endothelin-1 and human platelets. Curr Vasc Pharmacol 2005; 3: 393 - 399.
151. Liberopoulos EN, Mikhailidis DP, Elisaf MS. Diagnosis and management of the metabolic syndrome in obesity. Obesity Revs 2005; 6: 283 - 296.